# Ductal Carcinoma In Situ: Grading and Margin Assessment

## Introduction

Ductal carcinoma in situ (DCIS) is a non-invasive neoplastic proliferation of epithelial cells confined within the **basement membrane** of the mammary ducts. It accounts for approximately 20-25% of screen-detected breast cancers. Accurate grading, margin assessment, and biomarker evaluation are critical for guiding surgical and radiation therapy decisions.

## Histologic Architecture

DCIS displays several architectural patterns, often occurring in combination within the same specimen. The comedo pattern features central necrosis with calcification and high-grade nuclei, making it the most aggressive pattern. Cribriform DCIS shows rigid, punched-out (cookie-cutter) spaces within a monomorphic cell population. The micropapillary pattern consists of bulbous tufts projecting into duct lumens without fibrovascular cores. Solid DCIS fills ducts completely with a solid proliferation of neoplastic cells. The papillary pattern has true fibrovascular cores lined by neoplastic epithelium and characteristically lacks myoepithelial cells on those cores.

## Nuclear Grading

The **Van Nuys / consensus grading system** classifies DCIS into three nuclear grades.

| Grade | Nuclear Size | Chromatin / Nucleoli | Architecture | Necrosis | Calcification Type |
|---|---|---|---|---|---|
| 1 (Low) | 1.5–2× RBC | Evenly spaced, inconspicuous nucleoli | Cribriform, micropapillary | Rare | Psammomatous/laminated |
| 2 (Intermediate) | Moderate pleomorphism | Intermediate | Variable | May be present | Variable |
| 3 (High) | >2.5× RBC | Coarse chromatin, prominent nucleoli | Comedo, solid | Comedo necrosis | Amorphous/linear |

### Low-Grade (Grade 1)

Low-grade DCIS contains small, uniform nuclei measuring 1.5 to 2 times the size of a red blood cell, with inconspicuous nucleoli and evenly spaced chromatin. It often adopts a cribriform or micropapillary architecture, and the associated calcifications are typically **psammomatous or laminated**.

### Intermediate-Grade (Grade 2)

Intermediate-grade DCIS shows moderate nuclear pleomorphism, with features falling between low and high grade. Necrosis may or may not be present.

### High-Grade (Grade 3)

High-grade DCIS features large, pleomorphic nuclei exceeding 2.5 times the size of a red blood cell, with prominent nucleoli, coarse chromatin, and frequent mitoses. It is often accompanied by **comedo necrosis** with associated **amorphous or linear calcifications** and carries the highest risk of recurrence and progression to invasive carcinoma.

![DCIS grading comparison: low, intermediate, and high grade](images/dcis-grading.jpg)

## Comedonecrosis

Comedonecrosis refers to central luminal necrosis, often accompanied by dystrophic calcification. Historically designated as **comedo-type DCIS**, it is associated with higher grade and more aggressive behavior. Regardless of the nuclear grade assigned, the presence or absence of comedonecrosis should always be documented in the report.

## Margin Assessment

### Why Margins Matter

Adequate margins are the most important modifiable factor for reducing **local recurrence**. The 2016 SSO/ASTRO/ASCO consensus recommends a minimum margin of **2 mm** for DCIS treated with breast-conserving surgery and radiation.

### Reporting Margins

The pathology report should state the **closest margin and its distance in millimeters**. When DCIS extends to the inked margin, the margin is reported as **positive (involved)**. The extent of DCIS at or near the margin should be documented, and correct orientation of the specimen with adherence to inking protocols is critical for meaningful margin assessment.

### Challenges

DCIS often grows in a **discontinuous, segmental pattern** along the duct system, which complicates margin evaluation. Specimen processing with serial sectioning perpendicular to margins is the preferred approach, and **re-excision** should be considered for margins less than 2 mm.

![Margin assessment in breast-conserving surgery for DCIS](images/dcis-margin-assessment.jpg)

## Size Estimation

The **maximum extent** of DCIS should be measured using the number of involved slides and the intervening distances between them. Three-dimensional reconstruction may be necessary for large or multifocal DCIS. Size influences staging and drives treatment decisions such as the choice between mastectomy and lumpectomy.

## Biomarker Testing in DCIS

**ER/PR** status should be reported on all DCIS, as most low- and intermediate-grade DCIS is ER-positive. **HER2** testing is not routinely required but may be positive in approximately 60-70% of high-grade DCIS. Multigene assays such as the Oncotype DX DCIS score can aid in radiation therapy decisions for selected patients.

## Differential Diagnosis

**Atypical ductal hyperplasia (ADH)** is distinguished from low-grade DCIS by its smaller size, defined as less than 2 mm or involving fewer than 2 duct spaces. **Lobular carcinoma in situ (LCIS)** is E-cadherin negative and has different biology and management. **Cancerization of lobules** describes DCIS extending into lobules, which does not change the diagnosis. **Paget disease of the nipple** represents DCIS extending to the nipple epidermis.

![Cancerization of lobules by DCIS cells](images/dcis-cancerization-lobules.jpg)

## Clinical Pearls

The pathology report for DCIS should always include nuclear grade, presence of necrosis, architectural pattern, size, and margin status. The 2 mm margin threshold for DCIS is distinct from the "no ink on tumor" standard applied to invasive carcinoma. High-grade DCIS with comedo necrosis carries the highest risk of recurrence and progression to invasive disease. Microinvasion, defined as invasion extending 1 mm or less beyond the basement membrane, should be carefully sought and reported, as sentinel lymph node biopsy may be indicated when it is found.

## References

1. Morrow M, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. *J Clin Oncol*. 2016;34(33):4040-4046.
2. Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. *J Natl Cancer Inst Monogr*. 2010;2010(41):134-138.
3. Collins LC, et al. Pathology of ductal carcinoma in situ. *Surg Clin North Am*. 2018;98(4):677-691.
4. Lester SC, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. *Arch Pathol Lab Med*. 2009;133(1):15-25.